Adjuvant Breast Cancer Trials Collaborative Group (2007) Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy

Effects of Melatonin on IL-6 Serum Level Changes and Fatigue Caused by Adjuvant Chemoradiotherapy in Breast Cancer Women: A Randomized Controlled Trial

Introduction: Cancer-related fatigue is one of the most common and debilitating complications of breast cancer. Cancer patients have been found to have lower levels of melatonin, and fatigue has been shown to be correlated with both melatonin and interleukin (IL-6) in cancer patients. This study aimed to evaluate the fatigue and serum level of IL-6 in response to melatonin treatment in breast c...

Adjuvant Breast Cancer Trials Collaborative Group (2007) Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial,

Early breast cancer in the older woman.

BACKGROUND Women aged ≥65 are generally underrepresented in early breast cancer studies. Therefore, the optimal management of this group of women remains less certain. METHODS A literature review of recently published trials, reviews, and practice guidelines outlining the surgical and adjuvant management of early breast cancer in older women was performed. RESULTS Surgery remains as the cor...

Does adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?

Background: The primary objective of this study was to assess BMD change in Iranian females with breast cancer. Methods: A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spin...

Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so.

Adjuvant chemotherapy in older women diagnosed with lowrisk, estrogen receptor (ER)-positive breast cancer still inspires controversy. In fact, there is very little information on polychemotherapy in women aged 70 years or older (1), a direct result of our long-standing failure as cancer investigators to recruit older women to clinical trials. In this issue of the Journal, the International Bre...